Evidence map›Paper›PMID 37232264›Full record

ArticleCancer science2023

Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.

Michinori Ogura, Kazuhito Yamamoto, Yasuo Morishima, Masashi Wakabayashi, Kensei Tobinai, Kiyoshi Ando, Naokuni Uike, Mitsutoshi Kurosawa, Hiroshi Gomyo, Masafumi Taniwaki and 23 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 1 country.

Michinori OguraDepartment of Hematology, Aichi Sannomaru Clinic, Nagoya, Japan.
Kazuhito YamamotoDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.ORCID https://orcid.org/0000-0002-8588-8955
Yasuo MorishimaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Masashi WakabayashiJCOG Data Center, National Cancer Center Hospital, Tokyo, Japan.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kiyoshi AndoDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Naokuni UikeDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Mitsutoshi KurosawaDepartment of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Hiroshi GomyoDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Masafumi TaniwakiDepartment of Hematology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kisato NosakaDepartment of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan.ORCID https://orcid.org/0000-0001-6682-2451
Norifumi TsukamotoDepartment of Hematology, Gunma University Hospital, Maebashi, Japan.
Tatsu ShimoyamaDepartment of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Tokyo, Japan.
Noriko FukuharaDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Yoshihiro YakushijinFirst Department of Internal Medicine, Ehime University Graduate School of Medicine, Tohon-shi, Japan.ORCID https://orcid.org/0000-0001-6001-746X
Kazunori OhnishiDepartment of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kana MiyazakiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.ORCID https://orcid.org/0000-0001-6547-3181
Yoshihiro KameokaDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Nobuyuki TakayamaSecond Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Japan.
Ichiro HanamuraDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.ORCID https://orcid.org/0000-0002-6681-8927
Hirofumi KobayashiDepartment of Hematology, Saitama Cancer Center Hospital, Saitama, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1216-4470
Naoki KobayashiDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Kazuma OhyashikiDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Takahiko UtsumiDepartment of Hematology, Shiga General Hospital, Moriyama, Japan.
Kyoya KumagaiDepartment of Hematology, Chiba Cancer Center, Chiba, Japan.
Dai MaruyamaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0654-6920
Ken OhmachiDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.ORCID https://orcid.org/0000-0002-5530-818X
Yoshihiro MatsunoDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.
Shigeo NakamuraDepartment of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan.
Tomomitsu HottaNational Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Kunihiro TsukasakiDepartment of Hematology, National Cancer Center East, Kashiwa, Japan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Aichi Cancer Center · JPNational Hospital Organization · JPTokai University · JPTokyo National Hospital · JPAichi Medical University · JPAkita University · JPChiba Cancer Center · JPEhime University · JPGunma University Hospital · JPHamamatsu University · JPHokkaido University Hospital · JPHyogo Prefectural Cancer Center · JPKumamoto University · JPKyorin University · JPKyoto Prefectural University · JPMie University · JPNagoya Medical Center · JPNagoya University Hospital · JPNational Cancer Center Hospital East · JPNational Hospital Organization Hokkaido Medical Center · JP

Funding

Health and Labour Sciences Research Grants for Clinical Cancer Research 19-27Health and Labour Sciences Research Grants for Clinical Cancer Research 22-29National Cancer Center Research and Development Fund 2020-J-3National Cancer Center Research and Development Fund 23-A-16National Cancer Center Research and Development Fund 23-A-17National Cancer Center Research and Development Fund 26-A-4National Cancer Center Research and Development Fund 29-A-3The Ministry of Health, Labour and Welfare Grants-in-Aid for Cancer Research 16-6The Ministry of Health, Labour and Welfare Grants-in-Aid for Cancer Research 20S-1The Ministry of Health, Labour and Welfare Grants-in-Aid for Cancer Research 20S-6
6 · The paper itself

Abstract

Progression-free survival after R-High CHOP/CHASER/LEED with auto-PBSCT in untreated mantle cell lymphoma in JCOG0406 study. A continuous pattern of relapse was observed.

Indexed as

Lymphoma, Mantle-CellAdultAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFollow-Up StudiesHumansNeoplasm Recurrence, LocalPrednisoneRituximabVincristineCyclophosphamideDoxorubicinPrednisoneRituximabVincristine

Identifiers

PMID37232264
PMCPMC10394137
OpenAlexW4378347904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.